Overview

Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, randomized, 4 period, crossover, single-center trial. The purpose of this trial is to assess the relative bio-availability of racemate Oral Dispersible Tablet praziquantel (ODT-PQZ) (MSC1028703A) 150 milligram (mg) versus the current marketed praziquantel (PZQ) (Cysticide® 500 mg) formulation in healthy male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Praziquantel